CTX isoform | ||||
---|---|---|---|---|
Subjects | αL CTX/Cr | βL CTX/Cr | αD CTX/Cr | |
Premenopausal patients | Mean ± standard deviation | 3.65 ± 1.41 | 5.74 ± 3.46 | 1.75 ± 0.94 |
Postmenopausal patients | Mean ± standard deviation | 8.39 ± 3.01 | 13. 6 ± 3.9 | 3.62 ± 1.08 |
P, U testa | < 0.001 | < 0.001 | < 0.001 | |
T scorea | 3.4 | 2.3 | 2.0 | |
Normocalcemic breast cancer patients without bone metastases | Mean ± standard deviation | 10.2 ± 6.23 | 12.7 ± 11.3 | 4.73 ± 4.14 |
P, U testb | Not significant | Not significant | Not significant | |
Z scoreb | 0.60 | -0.23 | 1.03 | |
Normocalcemic breast cancer patients with bone metastases | Mean ± standard deviation | 22.6 ± 24.8 | 24.6 ± 18.4 | 7.95 ± 9.11 |
P, U testc | < 0.01 | < 0.01 | < 0.05 | |
Z scorec | 2.00 | 1.01 | 0.76 | |
Hypercalcemic breast cancer patients with bone metastases | Mean ± standard deviation | 35.1 ± 27.8 | 38.0 ± 23.7 | 11.3 ± 10.2 |
P, U testc | < 0.01 | < 0.01 | < 0.05 | |
Z scorec | 3.41 | 2.24 | 1.59 |